• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

[S-1同步放化疗后头颈部癌患者发生重度口腔黏膜炎的危险因素分析]

[Analysis of the Risk Factors for Severe Oral Mucositis in Head and Neck Cancer after Chemoradiotherapy with S-1].

作者信息

Nagatani Akiko, Ogawa Yumiko, Sunaga Tomiko, Tomura Kazuki, Naito Yuki, Fujii Naokazu, Okabe Takayuki, Hashimoto Touji, Kogo Mari, Sasaki Tadanori

机构信息

Departmant of Hospital Pharmaceutics, School of Pharmacy, Showa University.

出版信息

Yakugaku Zasshi. 2017;137(2):221-225. doi: 10.1248/yakushi.16-00077.

DOI:10.1248/yakushi.16-00077
PMID:28154335
Abstract

Radiotherapy (RT) and chemoradiotherapy (CRT) is widely accepted as the standard treatment for head and neck cancer (HNC). Oral mucositis (OM) often develops as an adverse reaction in HNC patients that receive RT or CRT involving S-1. However, little is known about the risk factors for OM in HNC patients. We retrospectively evaluated patients' pre-treatment clinical data in order to identify the risk factors for severe OM in HNC patients that are treated with RT or CRT involving S-1. We analyzed the cases of 129 patients who received RT or CRT involving S-1 for HNC. The endpoint of the survey was the occurrence of severe OM (≥grade 2). Risk factors that were significantly related to severe OM were identified using logistic regression analysis. The patients' mean age was 69.3±10.1 years, and 118 (92%) of the patients were male. The primary tumor was located in the oropharynx in 21.7% of cases. Severe OM occurred in 85.0% of cases. In the univariate analysis, the following variables were found to be associated with severe OM: age, the type of radiotherapy, disease stage, and chemotherapy. In the multivariate analysis, the location of the primary tumor and chemotherapy were identified as significant risk factors that contributed independently to the risk of severe OM (p<0.05). Our analysis suggests that cancer of the oropharynx and CRT are important risk factors for severe OM in HNC patients that undergo RT or CRT involving S-1.

摘要

放射治疗(RT)和放化疗(CRT)被广泛认为是头颈部癌(HNC)的标准治疗方法。口腔黏膜炎(OM)常作为接受涉及S-1的RT或CRT的HNC患者的不良反应而出现。然而,关于HNC患者发生OM的危险因素知之甚少。我们回顾性评估了患者的治疗前临床数据,以确定接受涉及S-1的RT或CRT的HNC患者发生严重OM的危险因素。我们分析了129例接受涉及S-1的RT或CRT治疗的HNC患者的病例。调查的终点是严重OM(≥2级)的发生情况。使用逻辑回归分析确定与严重OM显著相关的危险因素。患者的平均年龄为69.3±10.1岁,其中118例(92%)为男性。21.7%的病例中,原发肿瘤位于口咽。85.0%的病例发生了严重OM。在单因素分析中,发现以下变量与严重OM相关:年龄、放疗类型、疾病分期和化疗。在多因素分析中,原发肿瘤的位置和化疗被确定为严重OM风险的独立显著危险因素(p<0.05)。我们的分析表明,口咽癌和CRT是接受涉及S-1的RT或CRT的HNC患者发生严重OM的重要危险因素。

相似文献

1
[Analysis of the Risk Factors for Severe Oral Mucositis in Head and Neck Cancer after Chemoradiotherapy with S-1].[S-1同步放化疗后头颈部癌患者发生重度口腔黏膜炎的危险因素分析]
Yakugaku Zasshi. 2017;137(2):221-225. doi: 10.1248/yakushi.16-00077.
2
[The timing of the appearance of oral mucositis induced by concurrent chemoradiotherapy with S-1 for head and neck cancer].[同步放化疗联合S-1治疗头颈部癌所致口腔黏膜炎的出现时间]
Gan To Kagaku Ryoho. 2014 Dec;41(13):2571-5.
3
Phenylbutyrate mouthwash mitigates oral mucositis during radiotherapy or chemoradiotherapy in patients with head-and-neck cancer.苯丁酸局部用漱口液可减轻头颈部癌症患者放化疗期间的口腔黏膜炎。
Int J Radiat Oncol Biol Phys. 2012 Mar 15;82(4):1463-70. doi: 10.1016/j.ijrobp.2011.04.029. Epub 2011 Aug 11.
4
Adjuvant chemotherapy with S-1 after curative chemoradiotherapy in patients with locoregionally advanced squamous cell carcinoma of the head and neck: Reanalysis of the ACTS-HNC study.根治性放化疗后替吉奥辅助化疗治疗局部晚期头颈部鳞状细胞癌患者:ACTS-HNC 研究的再分析。
PLoS One. 2018 Jun 8;13(6):e0198391. doi: 10.1371/journal.pone.0198391. eCollection 2018.
5
[Concurrent chemoradiotherapy (CRT) with S-1 and cisplatin (CDDP) in patients (pts) with locally advanced head and neck cancer (HNC)].局部晚期头颈癌(HNC)患者采用S-1和顺铂(CDDP)同步放化疗(CRT)
Gan To Kagaku Ryoho. 2006 Jun;33 Suppl 1:167-71.
6
A phase II study of HMB/Arg/Gln against oral mucositis induced by chemoradiotherapy for patients with head and neck cancer.一项关于 HMB/Arg/Gln 预防头颈部癌症患者放化疗后口腔黏膜炎的 II 期临床研究。
Support Care Cancer. 2018 Sep;26(9):3241-3248. doi: 10.1007/s00520-018-4175-4. Epub 2018 Apr 7.
7
Effect of low-level laser therapy on patient reported measures of oral mucositis and quality of life in head and neck cancer patients receiving chemoradiotherapy--a randomized controlled trial.低水平激光疗法对接受放化疗的头颈部癌症患者口腔粘膜炎及生活质量的患者报告结果的影响:一项随机对照试验。
Support Care Cancer. 2013 May;21(5):1421-8. doi: 10.1007/s00520-012-1684-4. Epub 2012 Dec 8.
8
The association between cumulative radiation dose and the incidence of severe oral mucositis in head and neck cancers during radiotherapy.放疗中累积辐射剂量与头颈部癌症重度口腔黏膜炎发生率的关系。
Cancer Rep (Hoboken). 2021 Apr;4(2):e1317. doi: 10.1002/cnr2.1317. Epub 2020 Dec 9.
9
Confounding factors associated with oral mucositis assessment in patients receiving chemoradiotherapy for head and neck cancer.与头颈癌放化疗患者口腔黏膜炎评估相关的混杂因素。
Support Care Cancer. 2017 Sep;25(9):2743-2751. doi: 10.1007/s00520-017-3684-x. Epub 2017 Mar 28.
10
Multicenter phase II study of an oral care program for patients with head and neck cancer receiving chemoradiotherapy.一项针对接受放化疗的头颈癌患者口腔护理方案的多中心II期研究。
Support Care Cancer. 2016 Jul;24(7):3029-36. doi: 10.1007/s00520-016-3122-5. Epub 2016 Feb 18.

引用本文的文献

1
Risk factors for oral mucositis during chemotherapy treatment for solid tumors: a retrospective STROBE-guided study.实体瘤化疗治疗期间发生口腔黏膜炎的危险因素:一项基于 STROBE 指南的回顾性研究。
Med Oral Patol Oral Cir Bucal. 2022 Jul 1;27(4):e319-e329. doi: 10.4317/medoral.25253.
2
The association between cumulative radiation dose and the incidence of severe oral mucositis in head and neck cancers during radiotherapy.放疗中累积辐射剂量与头颈部癌症重度口腔黏膜炎发生率的关系。
Cancer Rep (Hoboken). 2021 Apr;4(2):e1317. doi: 10.1002/cnr2.1317. Epub 2020 Dec 9.